You are on page 1of 6

Annex, B.H., Williams, R.S., 1990.

Mitochondrial DNA structure and expression in
specialized subtypes of mammalian striated muscle. Mol. Cell. Biol. 10, 5671–
5678. doi:10.1128/MCB.10.11.5671.Updated
Antonetti, D.A., Reynet, C., Kahn, C.R., 1995. Increased expression of
mitochondrial-encoded genes in skeletal muscle of humans with diabetes
mellitus. J. Clin. Invest. 95, 1383–1388. doi:10.1172/JCI117790
Apostolova, N., Ballesteros, D., Monleo, D., Morales, J.M., Blas-garcı, A., Rocha,
M., Victor, V.M., Esplugues, J. V, 2010. Inhibition of Mitochondrial Function by
Efavirenz Increases Lipid Content in Hepatic Cells 115–125.
doi:10.1002/hep.23647
Apostolova, N., Gomez-Sucerquia, L.J., Gortat, A., Blas-Garcia, A., Esplugues, J. V,
2011. Autophagy as a rescue mechanism in Efavirenz-induced mitochondrial
dysfunction: A lesson from hepatic cells. Autophagy 7, 1402–1404.
doi:10.4161/auto.7.11.17653
Apostolova, N., Gomez-sucerquia, L.J., Moran, A., Alvarez, A., 2010. Enhanced
oxidative stress and increased mitochondrial mass during Efavirenz-induced
apoptosis in human hepatic cells. Br. J. Pharmacol. doi:10.1111/j.14765381.2010.00866.x
Arnoult, D., 2007. Mitochondrial fragmentation in apoptosis. Trends Cell Biol. 17,
6–12. doi:10.1016/j.tcb.2006.11.001
Autophagy, S., Apostolova, N., Gomez-sucerquia, L.J., Gortat, A., Blas-garcia, A.,
Esplugues, J. V, 2011. Compromising Mitochondrial Function with the
Antiretroviral Drug Efavirenz Induces Cell Survival-Promoting Autophagy.
Hepatology. doi:10.1002/hep.24459
Caggiari, L., Zanussi, S., Bortolin, M.T., D’andrea, M., Nasti, G., Simonelli, C.,
Tirelli, U., De Paoli, P., 2000. Effects of therapy with highly active anti-retroviral
therapy (HAART) and IL-2 on CD4+ and CD8+ lymphocyte apoptosis in HIV+
patients., Clinical and experimental immunology. doi:cei1187 [pii]
Carr, A., Cooper, D.A., 2000. Adverse drug reactions Adverse effects of
antiretroviral therapy. Lancet 356, 1423–1430.
Chaitanya, G.V., Steven, A.J., Babu, P.P., 2010. PARP-1 cleavage fragments:
signatures of cell-death proteases in neurodegeneration. Cell Commun. Signal. 8,
31. doi:10.1186/1478-811X-8-31
Chan, D.C., 2006. Mitochondria: dynamic organelles in disease, aging, and
development. Cell 125, 1241–52. doi:10.1016/j.cell.2006.06.010
Chazotte, B., 2011. Labeling mitochondria with JC-1. Cold Spring Harb. Protoc.
2011, 1103–1104. doi:10.1101/pdb.prot065490
Clercq, E. De, 2002. New developments in anti-HIV chemotherapy $. Biochim.
Biophys. Acta 1587, 258–275.

1997. G.J.. G.. Stern. Antiviral Res. N.1016/S10111344(96)07416-7 Fiala. MacDougall.J. Love. Curr. Current Protocols in Molecular Biology. Bethune. K. 1497– 1503. J. Effectiveness of Potent Antiretroviral Therapy on Time to AIDS and Death in Men With Known HIV Infection Duration 280. S.. H. Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation. T... doi:10. Montaner. Murphy... Methods Mol. Roger Brent. J. wiley. 2007. De. Sluis-cremer. H.A. 2012. Alexander. M.. M. Protoc.. et al. M... C. Kingston. Esplugues. L. doi:10.O. Giralt.L.003 . Hurrell. J. 1998. 2010. Wynhoven. 232–241. Toxicol.. HIV Res.ppat.. HAART drugs induce mitochondrial damage and intercellular gaps and gp120 causes apoptosis..antiviral. G.. Arthos....C. C. 2011. Zimmermann...P. J. W. N. Kingsley. L.E.. M.. R. H.H.. Curr. 219–229. Blas-garcia. 37. B Biol. doi:10. Craib. Gallagher. Profile of stress and toxicity gene expression in human hepatic cells treated with Efavirenz..G. V. A. J. J. 287–295. A.. P. Diaz-Delfin. J.. K. Biol. 346. L.. G. J. J.M. 4.1002/0471143030. Figueiredo.. Nat.. 327–337.. Immunoblotting and immunodetection. Robert E.. P.04. “mitochondria practical protocols”. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. 2006. Wong... F. Byrns. 2002.C. Scorrano. T. Dummin. Del Mar Gutierrez.. B. P.. Cell Biol.M..R. Frezza. Cashman. S.. Photochem. R. Drug-Induced Liver Injury Associated with the Use of Nonnucleoside Reverse-Transcriptase Inhibitors 10029. M. Mak.cb0602s52 Gallego-Escuredo.. 8.P. Photobiol. J. Brumme. 2003.A.. Detels. 372. J. V. O’Shaughnessy. L.. 545–53.. S.. Ting. J.S.. 2004. Dieterich.1056/NEJMoa012035 Dario Leister. 2004. M. J.T. Margolick.. Potent Nonnucleoside Reverse Transcriptase Inhibitors Target HIV-1 Gag-Pol.B. gene expression and release of adipokines and pro-inflammatory cytokines. Apostolova.E. Harrigan. Moore. A... Giorgi.0020119 Frederick M.. Ausubel. M. Yang. M. L. Fuller. Mcfarlane.S.. Cernay. Barbaro..K. Robinson. Iruela-Arispe.. Selective photosensitization of mitochondria in HeLa cells by cationic Zn(II)phthalocyanines with lipophilic side-chains. Marti-cabrera.2012. Protoc.. Harris.L.1371/journal. Mun. Organelle isolation: functional mitochondria from mouse liver. A.F. Buga. J. Domingo.. 811–20. Tachedjian. Luque. Domingo. D. Gomez-sucerquia.Côté.G. J.1016/j. J.. Phair. Cardiovasc.. N. muscle and cultured fibroblasts. Cipolat. 2. S..G..R. Winston. plos Pathog. 2007.. Schrager.A... 2. J. H. 94. Villarroya. doi:10.. J. Engl. Med. Mateo.W. L.. Z. doi:10.

W. I. Lu. Br. J. T. MITOCHONDRIAL TOXICITY OF NRTI ANTIVIRAL DRUGS : AN INTEGRATED CELLULAR PERSPECTIVE. Niekerk. 2000. Biopharm. J.1086/428842 Hamrapurkar. Goepferich.. Dis.. A. a. K. AIDS Res..03368. Z. K. T.. Binding of basic drugs to rat lung mitochondria. C. Sun. Day. Yuan... 2009. P. AIDS 1709–1717. Kakuda.1111/j.. J. 2008. Lymphocyte mitochondrial depolarization and apoptosis in HIV-1-infected HAART patients. Phale. Y. A. 516G → T ) and polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.1016/j. MITOCHONDRIAL TOXICITY OF NRTI ANTIVIRAL DRUGS : AN INTEGRATED CELLULAR PERSPECTIVE 2.1038/nrd1201 Lewis. V. Puga.C. doi:10. 2012. Ahmad.B. Appl. M. Z.. 22. Z.0b013e32830163ad Kwara. H. X. Shah. J.A. R.A. N. Wang. Snyman... Liu. S. M. Canton.W. doi:10. 8. 1987. doi:10. K. 812–822.. 2008. B. Ther. 1997..ejpb.. Dawood. 142–146. Sci. Copeland. 6.1016/S0092-8674(00)80434-1 Luo..014 Hori. Int.. Lartey. Clin.. Infect. Heller.D. Copeland. M. Talavera. 381–8. doi:10..... Zhai. George.1097/QAI. Lu. P.. Court.... Rzek.. 2010. Drug Discov. 2. Res. F. Gutierrez. 155– 165... G.... Ju... L..Gounden. Clin. M.. H..L.C.1365-2125. Rev. Karamchand.S.x Lewis. E. X. Nuclear entry of active caspase-3 is facilitated .2012. doi:10. Guo. 2010.M. Q. 1199–202.S. Wang. B. Zhang... Aberg. doi:10... Sagoe. Pharm.. 2003b. S. Eur.. Pharm. Targeting drugs to mitochondria.. 812–822. Okumura. doi:10. N.. 2010. doi:10. Clinical impact of patient population differences and genomic variation in efavirenz therapy. Syndr. E. 479–489..D. Presence of the CYP2B6 516G > T polymorphism . Van.. Yoshida. H.0b013e3181799662 King. D. N.N. 48.2009. Clin. Patil.1097/QAD. Nat... P. T. Nijhawan. Budihardjo.. S. Pharmacol.E. Pawar. Ther. 40.. 2005. CYP2B6 ( c . Srinivasula. J.. A. Brockhoff.. Immune Defic. 685–708.J.05. 4.J.. L. Cell 91. W.. A. Optimization and Validation of Rp-Hplc Stability-Indicating Method for Determination of Efavirenz and its Degradation Products. Ye. M. M. J.1038/nrd1201 Li. Disseminated histoplasmosis in patients with AIDS in Panama: a review of 104 cases. 1–9. 2003a. H. J.. increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. Chuturgoon.H. Day. A.. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. W. Alnemri. Cytochrome c and dATP-dependent formation of Apaf-1/caspase9 complex initiates an apoptotic protease cascade. Meng. Sosa. Acquir. W.

Chrousos. Greub.. 55– 63.2008. T.org/10. 1161–1167.doi.. Anal. 20. AIDS..L.. Chemother. M. Methods 65. Reardon. open-label observational study. N. Diseases. doi:10. J. Biochimie 76. Morand-joubert. 2007.. C.. Y. Trends Endocrinol..by its p3-recognition-based specific cleavage activity. Metab. J.. K. Acta . Chemother. 2008. I. Antimicrob. O. Journal of Acquired Immune Deficiency Syndromes. J. L.004 Martin. F.1093/jac/dkp334 Manfredi.K. F. Manoli. O. J... Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays..E. 38.029 . E. L... Buitelaar. A. J. L. M.. Infectieuses. 2009b.. Alesci.. De. Legrand.. F. Meynard. Mendoza. H.. De..A..9 Maggiolo. Biomed. Efavirenz versus nevirapine in current clinical practice: a prospective. S.M. Targeting lipophilic cations to mitochondria. Lacombe. Decosterd. 211–222.. M... doi:10. Barozzi. Agents Chemother.C. Pharm. J. C. Matthews. doi:10..1093/jac/dkn531 Mosmann. a. How single genes provide tRNA processing enzymes to mitochondria. 925–934. L. C. Matthews-Davis..2007. Antimicrob. Riuniti. Martin. J.S.1016/0022-1759(83)90303-4 Murphy. M. 190–8.1016/j.. Antimicrob. L. 1983. Mitochondrial DNA depletion in HIV-infected patients is more pronounced with chronic hepatitis C and enhanced following treatment with pegylated interferon plus ribavirin. Determination of efavirenz . G. in human plasma using HPLC with post-column photochemical derivatization and fluorescence detection. M. Girard.R. Hopper. Woolf.. S. Su.1016/j.tem. Pharmacie. 18.. a selective non-nucleoside reverse transcriptase inhibitor . Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1infected patients. 2009.. R. Antivir.1038/cr. Efavirenz : a decade of clinical experience in the treatment of HIV. Mitochondria as key components of the stress response. N.. A. 2005. G.P.. Brown. doi:10. Chiodo. Efavirenz : a decade of clinical experience in the treatment of HIV 910–928. Haddix-wiener. 2743–2749.bbabio.. R. Blackman. C. Biochim.J.E... A.Bioenerg. I. Rennert. Riuniti. Biophys. Telenti... doi:10.. Cell Res. Poirier. doi:10. E.. Timmermans.P. P..2010. Calza. 557–561. 579–584.04. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. doi:http://dx.. nuclei and the cytosol. Diseases.. 1994.. 2001. Ther. Immunol. J. Publique-ho.1093/jac/dkp334 Maggiolo.. Marzolini. 2004. O. 1994.P..03. 2009a. Barozzi. 28. Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C. De.. Mazenko. M. 2002. J. 910–928. Sánchez-conde.Z. I.

04. E..1001/jama. S... N. T.. J.1042/BJ20060919 Scorrano. F.. Ramesh.. J. Nunes.2011. B.J. doi:10. A. S.. E.... 46..2010...555 . Delaney. et al. P... S..H.1016/S1878-3317(10)60024-1 Ramachandran.. Clin. Blaikie. F. Biochem. doi:10.F. Med. Roat. S. Opening the doors to cytochrome c: changes in mitochondrial shape and apoptosis. 1998. Robertson. 99. Prime. K.1089/ars. J. S.O. Pilon. Chao. M..C.. Skulachev.. A.. Lysosomal-mitochondrial cross-talk during cell death.. Acad. Cardellach.. Zhivotovsky. 2002.. Bertoncelli. Structure of the apoptotic protease-activating factor 1 bound to ADP. Badley. E. Douglas.. Soler.. 926–933. 2010. A. Gomathi.. 2012. 2002. 53. Casademont. J. Phenix. Nature 434.. R. P. Natl. doi:10. 400. CYP2B6 G516T Polymorphism but Not Rifampin Coadministration Influences Steady-State Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus-Infected Patients in South India ᰔ.8..016 SM. Med. S. 555–570. Kumar.. R. Loveless. 2.A.A. Moorman. Turk. J. K. Swaminathan. V. U.. S. Porteous.P. 863–868. 47–55.1016/j. doi:10.1038/nature03465 Ross.J. A. Kjaergaard. Anitha. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Holmberg. doi:10. Da Ros. doi:10... Narendran. B.A.5. Milinkovic.. doi:10. JJ.2687 Pinti.d. Y. JAMA 300. Antimicrob. Satten. Redox Signal. C. doi:10.2009. Gatell. Mitophagy: A Complex Mechanism of Mitochondrial Removal... M. 662–9.G. 199–208.D. 41. Gibellini.. A.241655498 Palella..P.. D.Novak. Severina.. Gogvadze. L. Ther. Rajasekaran.. H.1056/NEJM199803263381301 Pedrol. Orrenius. Murphy. M.J.M.J. Smith.46. V.. Exp. De. Cossarizza... L. Kumar. F. W. B. L. Proc. Engl. Cytochrome c release from mitochondria proceeds by a two-step process. Lum..M. P. 853–860. Nasi.K..I. 2009. I. H. Menon. doi:10. 2006. Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection.J. Induction of Apoptosis by a Nonnucleoside Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor. J.H. Li. 1875–83.N.. U. Fuhrer. R. Cell Biol.A. Schwarzenbacher.... Accumulation of lipophilic dications by mitochondria and cells. Sci. C. Y.1073/pnas. M.. The Role of Mitochondria in HIV Infection and Its Treatment... Agents Chemother.M...1128/AAC. Agents Chemother.008 Riedl. Antivir.4407 Ott. A. 145–155. doi:10.300. 2008. A. Shi.. G.biocel. R. A. n. J.1128/AAC..07..D. doi:10. S. Mitochondrion 10. Antioxid.00899-08 Repnik. 2687–2691.mito. 2010. M. J. Biasi. 1259–63. M. Aschman. 2009. 2005. V. Biochem. I.. Antiretroviral treatment of adult hiv infection: 2008 recommendations of the international aids society–usa panel. G.. Int. J..D... 338. G. Antimicrob. T.1016/j.

T. doi:10.1023/A:1016119328968 Stankov.. Trends Endocrinol.16. Cell Biol..T.1042/BJ20070617 Usach. E. Pharmacol.. 2013. H. J...tem. 127–41. 1–14. Wang. Bausserman. 2009. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: An update.. M.M. L. X. A... M.18567 Walker..Soldani.M... Cell Res. V.03.1016/j.20074 Wasilewski. T. D. Agents Chemother. Annu.. 12. Apoptosis. Lücke. Jochen. doi:10.1. 2007..d.1038/cr. D.. I. Xu. Metab. 2012. Li. 2003. Rev. Alt... Lipid changes in patients initiating efavirenz. e1–2. Caspase-9 cleavage. doi:10. J.2009. Zanger. Y. AIDS Soc. doi:10. V. Lu. J. L. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics. HIV Clinical Trials. U.N. 227–256. Gatell.. A..1038/nrm3028 Zhu. M. do you need it? Biochem.-E. Liu.... Scorrano.1002/hep. doi:10.. Telenti.I.M. n.. 22. D.. Twiddy.. 287–94. B. J. 2008. Scovassi.and indinavir-based antiretroviral regimens. doi:10. C.N. R. safety and tolerability. 16. Pharmacogenetics of anti-HIV drugs. Chen. K. A. doi:10.82 . The changing shape of mitochondrial apoptosis. Melis.00914-09 Tashima. Caspase cleavage of cytochrome c1 disrupts mitochondrial function and enhances cytochrome c release. Mallolas. Peris. 2010. Das. U.P. 48.. 9–14. Toxicol.2011.. E.1128/AAC.007 Youle.7448/ias. Q. or Zalcitabine ¨. Behrens.. S. 2002. K.. doi:10. The. Antimicrob. G. Int... Aznar.J. 20. Hepatology 311–317. J. Cain. pharmacodynamics. Mechanisms of mitophagy.. Stavudine.P. Nat. Mitochondrial DNA Depletion and Respiratory Chain Activity in Primary Human Subcutaneous Adipocytes Treated with Nucleoside Analogue Reverse Transcriptase Inhibitors Mitochondrial DNA Depletion and Respiratory Chain Activity in Primary Human Subcutaneous.. M. T.. Mol. Depletion of Mitochondrial DNA in Liver Under Antiretroviral Therapy With Didanosine. Schmidt. 2011. E.. Narendra.A.. 405. Rev. Flanigan. Jin.